The second indigenous CAR-T cell therapy, Qartemi, has been approved by India's drug regulator. Qartemi is a "living drug" ...
Central Drugs Standard Control Organisation (CDSCO) on Friday released the list of Not of Standard Quality (NSQ) and Spurious ...
No Recommendations details available for this stock.
Aarti Drugs Ltd. key Products/Revenue Segments include Pharmaceuticals, Scrap and Export Incentives for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, the company has reported a ...